MacroGenics Inc. Reports Mixed Results in 2024 Annual Financial Report
MacroGenics Inc., a biopharmaceutical company focused on innovative antibody-based therapeutics for cancer treatment, has released its annual financial report for 2024. The report reveals a complex year for the company, characterized by significant fluctuations in revenue, ongoing legal challenges, and leadership changes.
1. Financial Performance Overview
Revenue Breakdown
In 2024, MacroGenics reported a total revenue of $149.9 million, a substantial increase from $58.74 million in 2023. This was primarily driven by a remarkable surge in revenue from collaborative agreements, which grew from $29.42 million in 2023 to $118.8 million in 2024, marking a staggering 303.98% increase. However, the company's product sales declined by 8.43%, falling to $16.42 million due to the strategic decision to sell the global rights to its FDA-approved product, MARGENZA, to TerSera Therapeutics for $40 million in November 2024.
Expenses and Net Income
Despite the increase in revenue, MacroGenics reported a net loss of $66.96 million for the year, exacerbated by heightened operational costs. Total costs and expenses surged to $260.5 million, driven largely by research and development expenses, which accounted for $177.1 million—up from $166.5 million in 2023. Selling, general, and administrative expenses also increased to $71.04 million, reflecting the company's investment in talent and operational capacity.
| Mar 2024 | Mar 2025 | |
|---|---|---|
Net Income | -9.05M | -66.96M |
Profit | -159.9M | -66.96M |
Net Income Continuing | -159.9M | -66.96M |
Income Tax Expense | 0 | 944K |
Pretax Income | -159.9M | -66.02M |
Non-operating Income | 8.25M | 44.55M |
Operating Income | -168.2M | -110.5M |
Revenue | 58.74M | 149.9M |
Costs and Expenses | 226.9M | 260.5M |
Cost of Revenue | 619K | 847K |
Operating Expenses | 226.3M | 259.6M |
Research & Development | 166.5M | 177.1M |
Selling, General & Administrative | 52.18M | 71.04M |
Other Operating Expenses | 7.60M | 11.45M |
Cash Flow and Liquidity
The company experienced a net change in cash of $81.88 million in 2024, a notable recovery from a cash decrease of $7.92 million in 2023. This positive cash flow was primarily attributed to significant proceeds from investment activities, including the sale of investments which amounted to $190 million.
| Mar 2024 | Mar 2025 | |
|---|---|---|
Net Change in Cash | -7.92M | 81.88M |
Net Cash from Operating Activities | -78.20M | -68.37M |
Operating Profit | -9.05M | -66.96M |
Adjustment to Operating Profit | -69.14M | -1.40M |
Net Cash from Investing Activities | -80.08M | 149.2M |
Investments | 78.38M | -112.8M |
Productive Assets | 1.7M | -36.45M |
Net Cash from Financing Activities | 150.3M | 960K |
Equity Issuance/Repurchase | 1.16M | 3.43M |
Other Financing Activities | 149.1M | -2.47M |
2. Balance Sheet Highlights
As of December 31, 2024, MacroGenics' total assets stood at $261.6 million, down from $298.4 million in the previous year. Current assets, particularly cash and equivalents, represented a substantial portion of total assets at $201.6 million. The company's liabilities remained stable at approximately $145.5 million, leading to total equity of $116 million.
| Mar 2024 | Mar 2025 | |
|---|---|---|
Total Assets | 298.4M | 261.6M |
Total Current Assets | 251.3M | 217.4M |
Cash and Equivalents | 100.9M | 182.8M |
Short-term Investments | 128.8M | 18.8M |
Net Inventories | 1.22M | 0 |
Accounts Receivable | 10.36M | 4.30M |
Prepaid Expenses | 9.94M | 11.51M |
Other Current Assets | 49K | 27K |
Total Non-current Assets | 47.07M | 44.16M |
Net PP&E | 21.84M | 18.1M |
Lease Assets | 23.8M | 24.5M |
Other Non-current Assets | 1.43M | 1.56M |
Total Liabilities and Equity | 298.4M | 261.6M |
Total Liabilities | 145.8M | 145.5M |
Total Current Liabilities | 56.10M | 55.53M |
Accounts Payable and Accrued Liabilities | 30.68M | 34.34M |
Current Debt | 3.77M | 4.86M |
Current Deferred Revenue | 21.65M | 16.31M |
Total Non-current Liabilities | 89.69M | 90.06M |
Non-current Deferred Revenue | 59.24M | 55.50M |
Other Non-current Liabilities | 30.45M | 34.56M |
Total Equity and Non-controlling Interests | 152.6M | 116.0M |
Total Equity | 152.6M | 116.0M |
3. Product Developments and Collaborations
Pipeline Progress
MacroGenics continues to advance its clinical pipeline, focusing on three proprietary product candidates: lorigerlimab, MGC026, and MGC028. The company has also maintained collaborations with notable entities like Incyte Corporation and Gilead Sciences, which are expected to further enhance its development pipeline.
Regulatory Challenges
Despite solid collaborative revenue growth, MacroGenics faced setbacks in product sales and regulatory challenges. The sale of MARGENZA has impacted the company's revenue mix, leading to concerns regarding the sustainability of product sales moving forward.
4. Leadership Changes and Legal Proceedings
The year was also marked by significant leadership changes, including the departure of the CEO, which resulted in increased stock-based compensation and severance expenses. Furthermore, MacroGenics has been embroiled in various legal proceedings, including a putative securities class action related to allegations of misstatements concerning clinical trial data.
Legal Proceedings Overview
In July 2024, a securities class action was filed against MacroGenics, claiming violations of securities laws. While the case was dismissed without prejudice in December 2024, the company remains vigilant as it navigates ongoing litigation risks.
5. Outlook for 2025
Looking ahead, MacroGenics aims to leverage its strong cash position and collaborative agreements to drive product development and enhance shareholder value. The company anticipates continuing to draw upon available sources of capital to support its growth initiatives while addressing the challenges posed by the recent changes in leadership and ongoing legal matters.
In summary, while MacroGenics Inc. has experienced a year of considerable revenue growth in collaboration with partners, the company must navigate hurdles regarding product sales, operational costs, and legal disputes as it positions itself for future success in the competitive oncology market.
